Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen vs Etoposide for First Recurrence of Glioblastoma Multiforme
NCT04765098Phase 2Recruiting
- Sponsor
- American Health Staffing Group
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen in glioblastoma multiforme (GBM), sponsored by American Health Staffing Group. Started Jan 2022; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04765098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765098.